7/22/2024  7:05:06 PM Chg. +0.5700 Volume Bid9:59:53 PM Ask9:58:10 PM Market Capitalization Dividend Y. P/E Ratio
38.4450EUR +1.50% 749
Turnover: 28,706.1150
-Bid Size: - -Ask Size: - 8.77 bill.EUR - -

Business description

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).

Management board & Supervisory board

Thierry Bernard
Management board
Roland Sackers, Fernando Beils, Stephany Foster, Antonio Santos, Nitin Sood, Dr. Jonathan Sheldon, Jean-Pascal Viola
Supervisory board
Lawrence A. Rosen, Dr. Metin Colpan, Dr. Toralf Haag, Elizabeth E. Tallett, Prof. Dr. Elaine Mardis, Prof. Dr. Ross L. Levine, Dr. Eva Pisa, Steve Rusckowski, Bert van Meurs, Eva van Pelt

Company data

Address: Spoorstraat 50,NL-5911 KJ Venlo
Phone: +31-77-320-8400
Fax: +31-77-320-8409
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 60.00%
IPO date: 9/25/1997

Investor relations

Name: John Gilardi
IR phone: +49-2103-29-11711
IR Fax: -
IR e-mail: john.gilardi@qiagen.com

Company calendar

CW 31 | 7/31/2024 Interim Report 2nd Quarter/6 Months

Main Shareholders

Sun Life Financial, Inc. (MFS)
BlackRock, Inc.
The Vanguard Group, Inc.
Rue la Boetie SAS
Norges Bank